{"id":"pentavalent-rotavirus-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability"}]},"_chembl":null,"_dailymed":{"setId":"aaf3b24e-85fd-43ee-b657-2ee4df312ec3","title":"ROTATEQ (ROTAVIRUS VACCINE, LIVE, ORAL, PENTAVALENT) SOLUTION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains live attenuated (weakened) rotavirus strains representing five common serotypes. When administered orally, it replicates in the intestinal epithelium and induces both humoral and mucosal immune responses, generating antibodies and cellular immunity against rotavirus antigens. This prevents infection and severe disease caused by wild-type rotavirus.","oneSentence":"A live attenuated rotavirus vaccine that stimulates immune response against five rotavirus strains to prevent rotavirus gastroenteritis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:54.027Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of rotavirus gastroenteritis in infants and young children"}]},"trialDetails":[{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06967272","phase":"PHASE2","title":"PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-01-20","conditions":"Rotavirus Gastroenteritis","enrollment":400},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT02145000","phase":"PHASE3","title":"Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger","status":"COMPLETED","sponsor":"Epicentre","startDate":"2014-06","conditions":"Severe Rotavirus Gastroenteritis","enrollment":6586},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT05212935","phase":"","title":"A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, Italy","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2022-05","conditions":"Vaccination, Rotavirus Infections, Meningococcal Infections","enrollment":2000},{"nctId":"NCT05037435","phase":"PHASE3","title":"Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.","status":"COMPLETED","sponsor":"Limited Liability Company Pharm Aid","startDate":"2018-06-25","conditions":"Rotavirus Infections, Rotavirus Vaccines","enrollment":40},{"nctId":"NCT05032391","phase":"PHASE3","title":"Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood Immunization","status":"COMPLETED","sponsor":"Limited Liability Company Pharm Aid","startDate":"2019-02-22","conditions":"Rotavirus Infection","enrollment":100},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT02286895","phase":"PHASE4","title":"Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali","status":"COMPLETED","sponsor":"PATH","startDate":"2014-10","conditions":"Diarrhea Rotavirus","enrollment":600},{"nctId":"NCT02062385","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-30","conditions":"Rotavirus Gastroenteritis","enrollment":4040},{"nctId":"NCT01926015","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-19","conditions":"Rotavirus Disease","enrollment":192},{"nctId":"NCT02584816","phase":"PHASE3","title":"Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2015-11","conditions":"Rotavirus Gastroenteritis","enrollment":1500},{"nctId":"NCT02133690","phase":"PHASE3","title":"A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2014-05","conditions":"Rotavirus Gastroenteritis","enrollment":7500},{"nctId":"NCT03474055","phase":"PHASE2, PHASE3","title":"Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2017-10-30","conditions":"Rotavirus Gastroenteritis","enrollment":1500},{"nctId":"NCT02193061","phase":"PHASE3","title":"Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs","status":"COMPLETED","sponsor":"National Institute of Pediatrics, Mexico","startDate":"2013-11","conditions":"Rotavirus Vaccine","enrollment":1498},{"nctId":"NCT02542462","phase":"PHASE4","title":"Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-11","conditions":"Intussusception, Rotavirus Infections","enrollment":144},{"nctId":"NCT00443846","phase":"PHASE3","title":"RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-13","conditions":"Meningitis, Meningococcal, Rotavirus Infections","enrollment":247},{"nctId":"NCT02728869","phase":"PHASE1, PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants","status":"COMPLETED","sponsor":"MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.","startDate":"2016-06","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT01960725","phase":"PHASE4","title":"An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)","status":"COMPLETED","sponsor":"Dennis Clements","startDate":"2014-02","conditions":"Diarrhea, Gastroenteritis","enrollment":66},{"nctId":"NCT00718237","phase":"PHASE3","title":"Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Rotavirus, Gastroenteritis","enrollment":762},{"nctId":"NCT00496054","phase":"PHASE3","title":"Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Gastroenteritis, Rotavirus","enrollment":110},{"nctId":"NCT00362648","phase":"PHASE3","title":"Developing World Study for RotaTeq™ (V260-015)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03","conditions":"Vomiting, Diarrhea, Fever","enrollment":7504},{"nctId":"NCT00953056","phase":"PHASE1","title":"A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Rotavirus Gastroenteritis","enrollment":144},{"nctId":"NCT01003431","phase":"PHASE3","title":"A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12","conditions":"Rotavirus Gastroenteritis, Diphtheria, Tetanus","enrollment":""},{"nctId":"NCT00258154","phase":"PHASE3","title":"V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Rotavirus Disease","enrollment":403},{"nctId":"NCT00092456","phase":"PHASE3","title":"Consistency Lots Vaccine Study (V260-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-05","conditions":"Rotavirus Infections","enrollment":793},{"nctId":"NCT00090233","phase":"PHASE3","title":"Rotavirus Efficacy and Safety Trial (REST)(V260-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-01","conditions":"Rotavirus Infections","enrollment":69274},{"nctId":"NCT00092443","phase":"PHASE3","title":"Dose Confirmation Efficacy Study (V260-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09","conditions":"Rotavirus Infections","enrollment":1312},{"nctId":"NCT00166517","phase":"PHASE3","title":"V260 Registration Study (V260-013)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Rotavirus","enrollment":178},{"nctId":"NCT00130832","phase":"PHASE3","title":"Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Rotavirus Infections, Gastroenteritis","enrollment":735},{"nctId":"NCT00767364","phase":"PHASE1","title":"Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Michigan","startDate":"2009-07","conditions":"Short Bowel Syndrome","enrollment":8},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT00981669","phase":"PHASE1","title":"Rotavirus Vaccine Produced by Butantan Institute","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2009-03","conditions":"Rotavirus Infections","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RotaTeq®"],"phase":"marketed","status":"active","brandName":"Pentavalent rotavirus vaccine","genericName":"Pentavalent rotavirus vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"A live attenuated rotavirus vaccine that stimulates immune response against five rotavirus strains to prevent rotavirus gastroenteritis. Used for Prevention of rotavirus gastroenteritis in infants and young children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}